Skip to content

Effect of Exenatide on paroxysmal atrial fibrillation with type 2 diabetes mellitus: a single-center, randomized, double-blind, controlled trial

Effect of Exenatide on paroxysmal atrial fibrillation with type 2 diabetes mellitus: a single-center, randomized, double-blind, controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002652
Enrollment
Unknown
Registered
2019-10-09
Start date
2019-12-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

paroxysmal atrial fibrillation with type 2 diabetes mellitus

Interventions

Sponsors

Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Patients who were diabetes based on the criteria for diabetes in 1999 WHO, received insulin or oral therapy with diet; 2) Patients have recent onset AF or paroxysmal AF (duration of current episode is <48 hours), need to restore sinus rhythm; 3) Blood pressure above 90 /60 mmHg; 4) Stable hemodynamics, without electrical cardio version therapy; 5) Aged 18-80 years, eligible to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with structural heart disease: rheumatic heart disease, chronic pulmonary heart disease, viral myocarditis, congenital heart disease, after pacemaker implantation; 2) Combined effects of hyperthyroidism, pre-excitation syndrome, atrioventricular (AV) block, etc.; 3) Patients were diagnosed with acute coronary syndrome within 6 months; 4) Severe combined primary liver, kidney, hematopoietic system and endocrine system deficiency; 5) New York Heart Association (NYHA) Class>III heart failure; 6) AV Conduction block and QT-interval prolongation (Q-Tc > 480 ms), bradycardia (heart rate < 50 beats min ) Holter monitoring pauses longer than 2 s; 7) Pregnant or breast-feeding, allergic or psychiatric illness; 8) Patients with advanced disease; 9) Patients are allergic to Amiodarone or Exenatide; 10) Patients are or have been treated with amiodarone or other GLP-1R agonist.

Design outcomes

Primary

MeasureTime frame
The duration of AF;The average time of conversion;FS;Blood sugar levels;LVEF;The frequency of AF;

Countries

China

Contacts

Public ContactPeng Cao

Jiangsu Province Hospital on Integration of Chinese and Western Medicine

cao_lab@126.com+86 025-85608666

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026